Revenue GrowthThe significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.

Bears Say

Cash Flow TimingThe timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.

Script GrowthNegative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.

Shield Therapeutics News

Shield Therapeutics Doubles ACCRUFeR® Revenues in Q2 2025

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported a significant increase in...

15d ago

Shield Therapeutics Secures Shareholder Support at 2025 AGM

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced the successful passing of all resolutions...

3M ago

Shield Therapeutics Reports Strong 2024 Financial Growth and Global Expansion of ACCRUFeR®

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics reported significant financial growth in...

4M ago

Shield Therapeutics Partners with VITAL-NET for ACCRUFeR® Launch in Japan

An update from Shield Therapeutics ( ($GB:STX) ) is now available. Shield Therapeutics has entered into an exclusive...

4M ago

Shield Therapeutics Reports Q1 2025 Revenue Growth and Strategic Progress

The latest update is out from Shield Therapeutics ( ($GB:STX) ). Shield Therapeutics reported a Q1 2025 trading...

4M ago

Shield Therapeutics Launches ACCRUFeR® in Canada to Address Iron Deficiency Anemia

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics plc has launched ACCRUFeR® in Canada, marking...

5M ago

Cautious Hold Rating on Shield Therapeutics Amidst Positive Financials and Prescription Growth Concerns

Analyst James Orsborne of Stifel Nicolaus maintained a Hold rating on Shield Therapeutics (STX – Research Report), boosting...

6M ago

Shield Therapeutics CEO Increases Stake, Signaling Confidence in Company’s Strategic Direction

Shield Therapeutics ( ($GB:STX) ) has issued an announcement. Shield Therapeutics announced that its Chief Executive Officer, Anders...

6M ago

Shield Therapeutics Grants Share Options to New CEO to Strengthen Market Position

Shield Therapeutics ( ($GB:STX) ) has issued an update. Shield Therapeutics announced the grant of share options to...

6M ago

Shield Therapeutics Hold Rating: Balancing Revenue Growth with Prescription Challenges and Financial Uncertainty

Stifel Nicolaus analyst James Orsborne maintained a Hold rating on Shield Therapeutics (STX – Research Report) yesterday and...

6M ago

STX FAQ

What was Shield Therapeutics’s price range in the past 12 months?

Shield Therapeutics lowest share price was $2.10 and its highest was $5.87 in the past 12 months.

What is Shield Therapeutics’s market cap?

Shield Therapeutics’s market cap is $46.88M.

When is Shield Therapeutics’s upcoming earnings report date?

Shield Therapeutics’s upcoming earnings report date is Sep 04, 2025 which is in 28 days.

How were Shield Therapeutics’s earnings last quarter?

Shield Therapeutics released its earnings results on Apr 24, 2025. The company reported -$0.011 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.002.

Is Shield Therapeutics overvalued?

According to Wall Street analysts Shield Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Shield Therapeutics pay dividends?

Shield Therapeutics does not currently pay dividends.

What is Shield Therapeutics’s EPS estimate?

Shield Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Shield Therapeutics have?

Shield Therapeutics has 1,041,690,400 shares outstanding.

What happened to Shield Therapeutics’s price movement after its last earnings report?

Shield Therapeutics reported an EPS of -$0.011 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -3.83%.

Which hedge fund is a major shareholder of Shield Therapeutics?

Currently, no hedge funds are holding shares in GB:STX

Shield Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-396.71%

Trailing 12-Months

Asset Growth

19.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Shield Therapeutics

Shield Therapeutics plc (STX) is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The company primarily operates in the healthcare sector, with a core emphasis on its lead product, Feraccru®/Accrufer®, an oral treatment for iron deficiency. Shield Therapeutics aims to address unmet medical needs with innovative therapies that offer significant advantages over existing treatments.